Contact

Empowering Care,
One Heart at a Time

Elucid is a medical technology company that develops AI to see invisible features of cardiovascular risk.

The company is dedicated to developing a clinical platform to help physicians deliver CCTA-guided personalized care by providing a more precise view of atherosclerosis, the root cause of cardiovascular disease.

Our Mission Statement

Elucid’s mission is to predict and personalize the prevention of heart attacks and strokes.

At Elucid, we focus on enabling efficient and transparent clinical insights to help usher in the next generation of CCTA-guided, personalized coronary artery disease care. We develop AI tools to see invisible features of risk and guide personalized, precise treatment based on a detailed analysis of patients’ atherosclerotic disease. Elucid’s platform transforms CT images into a dynamic, interactive map of disease, providing a more precise view of atherosclerosis – the root cause of cardiovascular disease – to help physicians personalize care based on a patient’s individual anatomy.

A smiling couple walks arm-in-arm through a vibrant outdoor market full of fresh vegetables and flowers.

Elucid Leadership

Andrew Miller Chief Technology Officer & SVP, Engineering

Andrew Miller

Chief Technology Officer & SVP, Engineering
Linkedin
Windi Hary Chief Regulatory & Quality Officer

Windi Hary

Chief Regulatory & Quality Officer
Linkedin
Amy Kruglak SVP, People & Leadership Development

Amy Kruglak

SVP, People & Leadership Development
Linkedin
Amir Ahmadi, MD Lead Scientific Advisor

Amir Ahmadi, MD

Lead Scientific Advisor
Linkedin

News, Media & Thought Leadership

Stay informed with the latest updates, insights, and conversations from Elucid.
Type
Slide announcing Elucids PlaqueIQ CMS reimbursement, featuring medical imaging and a highlighted artery model.

Elucid Gains Broad CMS Reimbursement of Coronary Plaque Analysis Using PlaqueIQ™

Elucid has announced new Hospital Outpatient Prospective Payment (OPPS) and Physician Fee Schedule (PFS) decisions from the U.S. Centers for Medicare & Medicaid Services (CMS) that establish significant reimbursement for coronary plaque analysis using PlaqueIQ across care settings.
  • Press Releases
Medical software ad showing artery scans and text about ELUCID’s new CT-based plaque analysis for carotid arteries.

Elucid Launches PlaqueIQ Image Analysis Software for the Carotid Arteries

Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, announced the launch of its PlaqueIQTM image analysis software for the quantification and classification of plaque morphology in the carotid arteries.
  • Press Releases
Announcement that Elucid’s PlaqueIQ software is now covered by United Healthcare, with a plaque artery illustration.

Elucid’s PlaqueIQ™ Image Analysis Software Now Covered by United Healthcare

Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, announced that United Healthcare has updated its cardiac imaging guidelines to fully align with recent recommendations from radiology benefit manager EviCore.
  • Press Releases
Elucid names Richard E. Kuntz and Shamiram Feinglass as board directors; text with headshots on blue background.

Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors

Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has made two additions to its Board of Directors. The company named Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH as board directors.
  • Press Releases
News graphic: Elucid applauds CMS inclusion of plaque analysis in 2026 proposed Medicare fee schedule.

Elucid Applauds CMS Inclusion of Coronary CTA with Plaque Analysis in 2026 Proposed Medicare Physician Fee Schedule

Elucid today released a statement commending U.S. Centers for Medicare & Medicaid Services (CMS) for the inclusion of a Category I CPT code for coronary plaque analysis and a national Medicare average payment amount of over $1,000, pending the final Medicare Physician Fee Schedule (PFS) ruling, which will come out in November.
  • Press Releases
Curved modern building with many windows, set against a clear blue sky with a small white cloud.

Where to Find Us: Upcoming Events

Washington Hilton – Washington, DC – March 7-10, 2026

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Click here

Stay in Touch

Subscribe to our newsletter for the latest clinical, product and regulatory updates.

Opt In
Eight people in an office sit and stand together, smiling and making heart shapes with their hands.